ACA
Acorn Capital Advisors Portfolio holdings
AUM
$153M
This Quarter Return
+3.01%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$153M
AUM Growth
+$153M
(+2%)
Cap. Flow
-$13.9M
Cap. Flow
% of AUM
-9.1%
Top 10 Holdings %
Top 10 Hldgs %
83.28%
Holding
22
New
–
Increased
7
Reduced
5
Closed
1
Top Buys
| 1 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$3.35M |
| 2 |
Candel Therapeutics
CADL
|
$2.17M |
| 3 |
Protara Therapeutics
TARA
|
$1.43M |
| 4 |
Y-mAbs Therapeutics
YMAB
|
$828K |
| 5 |
Puma Biotechnology
PBYI
|
$656K |
Top Sells
| 1 |
X4 Pharmaceuticals
XFOR
|
$13.6M |
| 2 |
OPTN
OptiNose
OPTN
|
$3.88M |
| 3 |
UroGen Pharma
URGN
|
$3.51M |
| 4 |
Mural Oncology
MURA
|
$1.52M |
| 5 |
Cardiff Oncology
CRDF
|
$106K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $29.4M | 19.24% | 1,131,501 | – | – |
|
|
2
UroGen Pharma
URGN
$900M
| $17.3M | 11.29% | 1,259,749 -256,554 | -17% | -$3.51M |
|
|
3
Y-mAbs Therapeutics
YMAB
$388M
| $15.4M | 10.09% | 3,418,995 +183,608 | +6% | +$828K |
|
|
4
Puma Biotechnology
PBYI
$254M
| $14.2M | 9.27% | 4,131,299 +191,247 | +5% | +$656K |
|
|
5
Candel Therapeutics
CADL
$318M
| $13.1M | 8.54% | 2,580,517 +428,265 | +20% | +$2.17M |
|
6
Trevi Therapeutics
TRVI
$883M
| $11.7M | 7.67% | 2,144,844 | – | – |
|
7
Terns Pharmaceuticals
TERN
$609M
| $7.35M | 4.81% | 1,971,264 | – | – |
|
|
OKUR
8
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $6.79M | 4.44% | 2,839,674 +1,400,000 | +97% | +$3.35M |
|
|
CYBN
9
Cybin
CYBN
$176M
| $6.16M | 4.03% | 734,394 | – | – |
|
|
BCAX
10
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $5.98M | 3.91% | 643,382 | – | – |
|
|
11
Protara Therapeutics
TARA
$120M
| $5.31M | 3.47% | 1,752,115 +472,315 | +37% | +$1.43M |
|
|
12
Cardiff Oncology
CRDF
$140M
| $4.44M | 2.9% | 1,408,767 -33,541 | -2% | -$106K |
|
13
Aura Biosciences
AURA
$389M
| $3.73M | 2.44% | 595,744 +5,236 | +0.9% | +$32.8K |
|
14
Verastem
VSTM
$569M
| $3.23M | 2.12% | 779,498 | – | – |
|
|
WHWK
15
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $2.13M | 1.39% | 1,139,363 | – | – |
|
16
BioAtla
BCAB
$26.7M
| $1.91M | 1.25% | 4,835,111 +803,065 | +20% | +$318K |
|
|
17
Mural Oncology
MURA
$35.7M
| $1.61M | 1.06% | 653,779 -615,936 | -49% | -$1.52M |
|
18
VYNE Therapeutics
VYNE
$8.16M
| $1.22M | 0.79% | 736,572 -49,366 | -6% | -$81.5K |
|
19
Q32 Bio
QTTB
$20.9M
| $1.2M | 0.78% | 803,425 | – | – |
|
20
Acrivon Therapeutics
ACRV
$42.2M
| $482K | 0.32% | 405,237 | – | – |
|
|
21
X4 Pharmaceuticals
XFOR
$84.2M
| $292K | 0.19% | 153,730 -7,156,920 | -98% | -$13.6M |
|
|
OPTN
22
DELISTED
OptiNose
OPTN
| – | – | -422,814 | Closed | -$3.88M |
|